Sanofi stock: 1.9 billion US dollar Dren Bio deal targets autoimmunity

Sanofi is expanding its immunology pipeline through a deal to buy an autoimmune drug from Dren Bio. Pharmaphorum reported the transaction on Wednesday, November 11, 2026, and put its potential value at 1.9 billion US dollars.

The agreement gives Sanofi exposure to deep B-cell depletion, an emerging approach in autoimmune medicine. The transaction adds another development path to a portfolio that already depends heavily on established immunology products and newer launches.

Pipeline expansion adds strategic weight

For Sanofi, the deal is more than a single-asset purchase. It broadens the company's options in a field where selective removal of B cells is being explored for immune-mediated diseases. The value of the opportunity will depend on the drug's clinical progress, regulatory profile and eventual commercial positioning.

The acquisition also puts business development at the center of the investment case. A stronger pipeline can help Sanofi offset the long-term pressure that comes with reliance on major products, but purchased assets carry execution risk until clinical milestones and market potential become clearer.

The immediate market information remained limited to the live European quote. Sanofi stock traded at 86.05 euros on Lang & Schwarz at 11:51 CET on Wednesday, November 11, 2026.

Healthcare shares remain part of the broader French market represented by the CAC 40.

For more company developments, see More news and analyses on Sanofi stock.